SI-BONE (SIBN) Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SIBN shares.
View SIBN analyst ratings or view top-rated stocks.

7 brokers have issued 1 year price targets for SI-BONE's stock. Their SIBN share price forecasts range from $20.00 to $32.00. On average, they predict the company's share price to reach $25.29 in the next year. This suggests that the stock has a possible downside of 4.1%.
View analysts price targets for SIBN or view top-rated stocks among Wall Street analysts.

SI-BONE's stock was trading at $13.60 at the beginning of the year. Since then, SIBN stock has increased by 93.8% and is now trading at $26.36.
View the best growth stocks for 2023 here.

SI-BONE saw a drop in short interest in May. As of May 15th, there was short interest totaling 786,800 shares, a drop of 28.5% from the April 30th total of 1,100,000 shares. Based on an average daily trading volume, of 395,700 shares, the short-interest ratio is presently 2.0 days.
View SI-BONE's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our SIBN earnings forecast.

SI-BONE, Inc. (NASDAQ:SIBN) issued its earnings results on Monday, November, 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.06. The company earned $22.29 million during the quarter, compared to analyst estimates of $22.71 million. SI-BONE had a negative net margin of 47.11% and a negative trailing twelve-month return on equity of 54.17%. During the same period in the previous year, the business earned ($0.33) EPS.

ETFs with the largest weight of SI-BONE (NASDAQ:SIBN) stock in their portfolio include Hypatia Women CEO ETF (WCEO), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED) and iShares Micro-Cap ETF (IWC).iShares U.S. Medical Devices ETF (IHI) and

SI-BONE issued an update on its FY 2023 earnings guidance on Monday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $128.00 million-$131.00 million, compared to the consensus revenue estimate of $125.45 million.

10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).

(SIBN) raised $84 million in an initial public offering on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."

SI-BONE's stock is owned by many different retail and institutional investors. Top institutional shareholders include Brown Advisory Inc. (11.24%), BlackRock Inc. (7.82%), First Light Asset Management LLC (6.01%), Champlain Investment Partners LLC (4.85%), Granahan Investment Management LLC (3.35%) and Next Century Growth Investors LLC (3.23%). Insiders that own company stock include Anshul Maheshwari, Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky and Michael A Pisetsky.
View institutional ownership trends.

Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SIBN stock can currently be purchased for approximately $26.36.

SI-BONE (NASDAQ:SIBN) has a market capitalization of $927.34 million and generates $106.41 million in revenue each year. The company earns $-61,260,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

The company employs 352 workers across the globe.

SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The official website for the company is www.si-bone.com. The company can be reached via phone at (408) 207-0700 or via email at investors@si-bone.com.